NO20005498L - Form av 1-(6-klornaft-2-ytsulfonyl)-4-[4-(4- pyridyl)benzoyl]piperazin med redusert partikkelstörrelse - Google Patents

Form av 1-(6-klornaft-2-ytsulfonyl)-4-[4-(4- pyridyl)benzoyl]piperazin med redusert partikkelstörrelse

Info

Publication number
NO20005498L
NO20005498L NO20005498A NO20005498A NO20005498L NO 20005498 L NO20005498 L NO 20005498L NO 20005498 A NO20005498 A NO 20005498A NO 20005498 A NO20005498 A NO 20005498A NO 20005498 L NO20005498 L NO 20005498L
Authority
NO
Norway
Prior art keywords
naphth
piperazine
sulfonyl
pyridyl
benzoyl
Prior art date
Application number
NO20005498A
Other languages
English (en)
Other versions
NO20005498D0 (no
Inventor
Marianne Ashford
Roger James
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20005498D0 publication Critical patent/NO20005498D0/no
Publication of NO20005498L publication Critical patent/NO20005498L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20005498A 1998-05-02 2000-11-01 Form av 1-(6-klornaft-2-ytsulfonyl)-4-[4-(4- pyridyl)benzoyl]piperazin med redusert partikkelstörrelse NO20005498L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809350.3A GB9809350D0 (en) 1998-05-02 1998-05-02 Novel salt
PCT/GB1999/001316 WO1999057112A1 (en) 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine

Publications (2)

Publication Number Publication Date
NO20005498D0 NO20005498D0 (no) 2000-11-01
NO20005498L true NO20005498L (no) 2000-11-01

Family

ID=10831311

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005498A NO20005498L (no) 1998-05-02 2000-11-01 Form av 1-(6-klornaft-2-ytsulfonyl)-4-[4-(4- pyridyl)benzoyl]piperazin med redusert partikkelstörrelse

Country Status (16)

Country Link
EP (1) EP1084118A1 (no)
JP (1) JP2002513789A (no)
KR (1) KR20010043216A (no)
CN (1) CN1308629A (no)
AU (1) AU3719699A (no)
BR (1) BR9910176A (no)
CA (1) CA2331041A1 (no)
EE (1) EE200000638A (no)
GB (1) GB9809350D0 (no)
HU (1) HUP0102394A3 (no)
IL (1) IL139405A0 (no)
NO (1) NO20005498L (no)
PL (1) PL343705A1 (no)
SK (1) SK16522000A3 (no)
WO (1) WO1999057112A1 (no)
ZA (1) ZA200006036B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525042B1 (en) 1997-09-30 2003-02-25 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
DE69835430T2 (de) * 1997-05-30 2007-03-08 Takeda Pharmaceutical Co. Ltd. Sulfonamidderivate, ihre herstellung und verwendung
US6525042B1 (en) * 1997-09-30 2003-02-25 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives

Also Published As

Publication number Publication date
NO20005498D0 (no) 2000-11-01
SK16522000A3 (sk) 2001-05-10
WO1999057112A1 (en) 1999-11-11
KR20010043216A (ko) 2001-05-25
ZA200006036B (en) 2002-01-25
HUP0102394A3 (en) 2003-01-28
HUP0102394A2 (hu) 2001-12-28
EP1084118A1 (en) 2001-03-21
GB9809350D0 (en) 1998-07-01
CA2331041A1 (en) 1999-11-11
BR9910176A (pt) 2001-01-09
JP2002513789A (ja) 2002-05-14
PL343705A1 (en) 2001-08-27
EE200000638A (et) 2002-04-15
AU3719699A (en) 1999-11-23
CN1308629A (zh) 2001-08-15
IL139405A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
HK5288A (en) 2-[4-[(4,4-dialkyl-2, 6-piperidinedion-1-yl) butyl]-1-piperazinyl]pyrimidines
NO20015746L (no) Ny anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2- karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptablesalter
NO924764L (no) 4-pyrimidinyl- og pyridinylderivater av indol-3-yl-alkylpiperazin
DE60125980D1 (de) P38kinase-inhibitoren vom piperidin/piperazin-typ
NO20000115L (no) Gastrokinetiske monocykliske benzamidler av 3- eller 4- substituerte 4-(aminometyl)-piperidinderivater
DE60142613D1 (de) Aryl substituierte pyridinen, pyrimidinen, pyrazinen und triazinen und deren verwendung
NO940881D0 (no) Enantiomerer av 1-[(4-klorfenyl)fenylmetylÅ-4-[(4-metylfenyl)sulfonylÅpiperazin
AU4994693A (en) 4-{2-(4-(2-pyridinyloxy)phenyl)ethoxy}-quinazoline and analogues thereof
CH1175401H1 (de) Piperazin Derivate verwendbar als CCR5 Antagonisten
FI964815L (fi) Piperatsiinijohdoksia 5-HT1A antagonisteina
ME00901B (me) Mezilat trihidrat 5-(2-(4-(1 ,2-benzizotiazol-3-il)-1-piperazinil)-etil)-6-hlor0-1,3-dihidr0-2h-indol-2-ona
DE69731094D1 (de) MESYLATDIHYDRATSALZE von 5-(2-(4-(1,2-BENZISOTHIAZOL-3-yl)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ON (=ZIPRASIDONE), DESSEN HERSTELLUNG UND VERWENDUNG ALS DOPAMIN-D2-ANTAGONIST
ES8402832A1 (es) Un procedimiento para la preparacion de compuestos dotados de propiedades psicotropicas.
DE69106388D1 (de) Antipsychotische 4-(1,2-benzisoazolyl)piperidinderivate.
ATE196294T1 (de) Piperazin-derivate und ihre verwendung als 5-ht1a-antagoniste
NO20005498L (no) Form av 1-(6-klornaft-2-ytsulfonyl)-4-[4-(4- pyridyl)benzoyl]piperazin med redusert partikkelstörrelse
NO894650D0 (no) Fremgangsmaate for fremstilling av 2-(2-(4-((4-klorfenyl)-fenylmethyl)-piperazinyl)-ethoxy)-eddiksyre og dens dihydroklorid.
NO20013832D0 (no) Piperidin- og piperazinderivater som hemmere ved Abeta-fibril- dannelsen
NO20002631D0 (no) Pseudopolymorfe former av 2-[2-[4-(bis(4-fluorfenyl)metyl]-1- piperazinyl]etoksy]eddiksyre dihydroklorid
FI955387L (fi) 4(p-fluorifenyyli)-3-((3,4-(metyleenioksi)fenoksi)metyyli)-piperidiinin N-p-halobentsoyylimetyylijohdannaiset
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
FI964114L (fi) Uusia 1-(5-metaanisulfonamidoindolyyli-2-karbonyyli)-4-(3-(1-metyylietyyliamino)-2-pyridinyyli)piperatsiinin kiteisiä muotoja
ATE298333T1 (de) Synthese von 4-(piperidyl) (2-pyridyl)methanon- (e)-o-methyloxim und seinen salzen
AU517046B2 (en) 4-[4-(2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl-methyl)-1-piperazinyl]-6-methyl pyrimidine derivatives
HK1095273A (en) Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application